Nurix Therapeutics to present new Phase 1a1b study data on BTK degrader bexobrutideg in CLLSLL

Traders Union
All News
Business & Wealth
Companies
Nurix to present new BTK data

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

05.11.2026

Nurix Therapeutics to present new Phase 1a1b study data on BTK degrader bexobrutideg in CLLSLL — Nurix to present new BTK data

Nurix Therapeutics announced it will share new and updated efficacy and safety results from its ongoing Phase 1a1b clinical study of the oral BTK degrader, bexobrutideg, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLLSLL).

The data will be presented in a poster session at the ASH2026 conference, highlighting progress in Nurix Therapeutics investigational program.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Nurix Therapeutics recently reported major progress in its BTK degrader clinical program alongside its Q3 2026 financial results. The company and Roche also enrolled the first patient in a Phase 1b2 trial of oral BTK degrader bexobrutideg for CLL. The latest data presentation follows these key milestones in its clinical development efforts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Nurix

Editor's Picks for You

From airline tickets to Ferraris: What can you buy with crypto?

By Pavlo Kot
23 hours ago

From airline tickets to Ferraris: What can you buy with crypto?

Editors' Picks

Apartment or Bitcoin: Choosing a safe haven for your wealth

By Pavlo Kot
Yesterday

Apartment or Bitcoin: Choosing a safe haven for your wealth

Editors' Picks

CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?

By Dmytro Kharkov
06.11.2026

CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?

Editors' Picks

All Editors' Top Picks

Latest Nurix News

BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results

By Igor Krasulya
12.10.2026

BTK degrader clinical program progresses as Nurix Therapeutics delivers Q3 2026 results

Companies

Nurix Therapeutics enrolls first patient in Phase 1b2 trial of oral BTK degrader for CLL

By Alena Volkova
07.10.2026

Nurix Therapeutics enrolls first patient in Phase 1b2 trial of oral BTK degrader for CLL

Companies

Gilead Sciences extends Nurix Therapeutics partnership by two years in oncology research

By Mykhailo Ihnatenko
05.10.2026

Gilead Sciences extends Nurix Therapeutics partnership by two years in oncology research

Companies

Pavlo Kot
23 hours ago

From airline tickets to Ferraris: What can you buy with crypto?

Pavlo Kot
Yesterday

Apartment or Bitcoin: Choosing a safe haven for your wealth

Dmytro Kharkov
06.11.2026

CVS Health’s $117B split: Defensive spin-off or end of healthcare vertical integration?

Anastasiia Chabaniuk
06.11.2026

Italy embraces blockchain, but remains wary of cryptocurrencies

Mikhail Vnuchkov
06.11.2026

From Wall Street to Bitcoin: A wave of panic sweeps across markets

Oksana Koneva
33 min ago

Adam Khoo: CEO exit risk is main concern for company with no clear successor

Eugene Komchuk
1 hour ago

Stephan Livera: Multi-sig poised to become standard for Bitcoin life savings

Hanna Syniavska
1 hour ago

Long-term Bitcoin holders experience major gains, Fred Krueger notes

Igor Krasulya
1 hour ago

Scott Melker: Anchorage Digital CEO questions value creation from tokenization and AI agents

Yaroslav Dmytrenko
1 hour ago

Crypto liquidations surpass $1 billion in 24 hours, David Gokhshtein notes

Top News

Andreas Kristo
17 hours ago

Taiwan slashes short-selling limit from 30% to 3% after market rout

Taiwan slashes short-selling limit from 30% to 3% after market rout

Mélissa Bac
19 hours ago

Asian markets rotate beyond semiconductors as AI stocks lose momentum

Asian markets rotate beyond semiconductors as AI stocks lose momentum

Jainam Mehta
19 hours ago

Berkshire Hathaway buybacks hit record $9.6B as Greg Abel shifts capital strategy

Berkshire Hathaway buybacks hit record $9.6B as Greg Abel shifts capital strategy

Pavlo Kot
23 hours ago

From airline tickets to Ferraris: What can you buy with crypto?

From airline tickets to Ferraris: What can you buy with crypto?

Mikhail Vnuchkov
Yesterday

Wall Street analysts urge investors to buy stocks after U.S. market rout

Wall Street analysts urge investors to buy stocks after U.S. market rout

Top 5 companies for you

United States

Live News

Pavlo Kot
Now

Binance hackers still hold $3.1 billion in cryptocurrency after attack

Mykhailo Ihnatenko
Now

AMD stock attempts recovery after sharp sell-off wipes out post-earnings gains

Anton Kharitonov
Now

EUR/USD slips toward 1.1170 as dollar demand rises ahead of NFP

Mykhailo Ihnatenko
Now

Ethereum price falls toward $2,200 as long liquidations hit $1.12B

Eugene Komchuk
Now

Google could acquire a stake in TeraWulf's AI project

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.